Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies

Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies

Abstract Plasma circulating tumour DNA (ctDNA) has been suggested to be a viable biomarker of response to treatment in patients with high grade serous ovarian carcinoma (HGSOC). TP53 mutations are present in more than 90% of HGSOCs but somatic variants are distributed across all exonic regions of th...

Full description

Bibliographic Details
Main Authors: Leslie Calapre, Tindaro Giardina, Aaron B. Beasley, Anna L. Reid, Colin Stewart, Benhur Amanuel, Tarek M. Meniawy, Elin S. Gray
Format: Article
Language:English
Published: Nature Portfolio 2023-01-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-27445-2

Internet

https://doi.org/10.1038/s41598-023-27445-2

Similar Items